ITRM

Iterum Therapeutics plc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website iterumtx.com
Employees(FY) 14
ISIN IE000TTOOBX0

Performance

+10.14%

+39.32%

+21.64%

+15.6%

-17.26%

YTD

+18.12%

Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Advanced Technical Analysis

Technical Analysis of ITRM 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 93, indicating robust upward momentum, while the Technical Score of 75 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ITRM

Stock Rank

Recent News & Updates

2024-11-14 13:10
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...(Yahoo Finance)
2024-11-13 18:00
Iterum Therapeutics Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-10 19:00
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024(Globenewswire)
2024-10-27 22:19
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships(Yahoo Finance)
2024-10-27 19:49
FDA approves Iterums ORLYNVAH NDA for uUTI treatment(Yahoo Finance)
2024-10-27 17:00
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections(Prnewswire)
2024-10-24 23:03
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections(Globenewswire)
2024-10-09 20:30
Iterum Therapeutics to Present Data at IDWeek 2024(Globenewswire)
2024-10-09 05:00
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-23 22:33
Iterums oral sulopenem acceptance hinges on antibiotic stewardship efforts(Yahoo Finance)
2024-09-09 19:00
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women(Globenewswire)
2024-09-06 04:30
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference(Globenewswire)
2024-08-16 20:09
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2024 Earnings Call Transcript(Insidermonkey)
2024-08-13 19:00
Iterum Therapeutics Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-09 20:18
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript(Insidermonkey)
2024-08-07 04:30
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024(Globenewswire)
2024-08-06 05:30
Iterum Therapeutics Announces Expiration and Results of Rights Offering(Globenewswire)
2024-08-01 20:00
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem(Globenewswire)
2024-07-21 19:30
Iterum Therapeutics Commences Rights Offering(Globenewswire)
2024-06-20 20:00
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections(Globenewswire)
2024-06-04 20:00
Iterum Therapeutics to Present Data at ASM Microbe 2024(Globenewswire)
2024-05-30 20:00
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections(Globenewswire)
2024-05-13 20:21
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-13 10:49
Q1 2024 Iterum Therapeutics PLC Earnings Call(Yahoo Finance)
2024-05-12 23:53
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-12 19:00
Iterum Therapeutics Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-05 20:00
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024(Globenewswire)
2024-04-28 20:00
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem(Globenewswire)
2024-04-01 22:22
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-04-01 22:22
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.